Realtime | Geld | Brief | Zeit |
---|---|---|---|
8,460 | 8,530 | 18:04 | |
8,460 | 8,530 | 17:54 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.10. | ADOCIA Reports Third Quarter 2025 Financial Results and Provides a Business Update | 272 | Business Wire | Cash position of €13.4 million as of September 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 ... ► Artikel lesen | |
15.10. | ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T1D | 367 | Business Wire | This Phase 3 clinical trial on BioChaperone Lispro (THDB0206 injection) conducted in China in people with Type 1 Diabetes, successfully demonstrated, in comparison with standard of care Humalog:
... ► Artikel lesen | |
10.10. | Number of Shares and Voting Rights of ADOCIA as of September 30th, 2025 | 205 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
25.09. | ADOCIA Announces First Half 2025 Financial Results and Provides a Business Update | 366 | Business Wire | Cash position of €7.1m (million) as of June 30, 2025 following successful completion of €9.7m private placement in February 2025
Cash runway secured until Q2 2026 considering the US$10... ► Artikel lesen | |
11.09. | Number of Shares and Voting Rights of ADOCIA as of August 31st, 2025 | 274 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
03.09. | ADOCIA Announces Oral Presentations on AdoShell and BioChaperone at EASD, ESB and PODD 2025 Annual Meetings | 1.981 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions... ► Artikel lesen | |
19.08. | Number of Shares and Voting Rights of ADOCIA as of July 31st, 2025 | 311 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
ADOCIA Aktie jetzt für 0€ handeln | |||||
25.07. | ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in People with T2D | 831 | Business Wire | This Phase 3 clinical trial on BioChaperone Lispro (THDB0206 injection) conducted in China in people with Type 2 diabetes, successfully demonstrated, in comparison with standard of care Humalog:
... ► Artikel lesen | |
23.07. | ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update | 584 | Business Wire | Cash position of €7.1 million as of June 30, 2025
US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025
Current... ► Artikel lesen | |
16.07. | ADOCIA Announces Half-Year Report on Adocia's Liquidity Agreement with Kepler Capital Markets | 423 | Business Wire | Regulatory News:
Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on... ► Artikel lesen | |
11.07. | Number of Shares and Voting Rights of ADOCIA as of June 30th, 2025 | 344 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
24.06. | ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell from Human Islets to Stem Cell-Derived Islets | 351 | Business Wire | Main results are:
successful scale up from animal to human device for First-In-Human study
in vitro and in vivo maturation after encapsulation of immature stem cell-derived islets in... ► Artikel lesen | |
12.06. | ADOCIA SA: Number of Shares and Voting Rights of ADOCIA as of May 31st, 2025 | 355 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
22.05. | ADOCIA Confirms its Eligibility for the PEA-PME Scheme | 397 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
21.05. | ADOCIA Announces its Annual Shareholders' Meeting to be Held on June 11th, 2025 in Paris | 395 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
15.05. | Number of Shares and Voting Rights of ADOCIA as of April 30th, 2025 | 310 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
14.05. | ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update | 380 | Business Wire | Cash position of €12.2 million as of March 31, 2025, including €9.7m from the private placement successfully completed in February 2025
Cash runway extended until Q2 2026
Top-line... ► Artikel lesen | |
30.04. | ADOCIA Announces the Release of its Universal Registration Document for the Year 2024 | 364 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
28.04. | ADOCIA to Present New Data on AdoShell at Upcoming Scientific Conferences - Showcasing Potential Curative Treatment for Type 1 Diabetes | 342 | Business Wire | Presentations demonstrate the potential of AdoShellfor allogenic cell therapy in diabetes without immunosuppression, by delivering pancreatic human islets or iPSCs1
New preclinical data support... ► Artikel lesen | |
17.04. | ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update | 473 | Business Wire | Cash position of €7.5m (million) as of December 31, 2024, including:
€2m received from private placement in March 2024
€9.8m from an equity financing line ("PACEO") with Vester Finance
... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,55 | -1,20 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
EVOTEC | 6,866 | +2,08 % | Evotec Aktie: Gefährlich! Breakversuch scheint erneut zu scheitern | Wieder läuft die Evotec Aktie auf massive charttechnische Hindernisse an der 7-Euro-Marke an - und wieder könnte sie scheitern. Im Handel am Donnerstag erreichte die Biotech-Aktie auf XETRA in der Spitze... ► Artikel lesen | |
BB BIOTECH | 41,300 | -2,02 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
MEDIGENE | 0,055 | -14,55 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
QIAGEN | 42,270 | +0,49 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
CUREVAC | 4,610 | -0,52 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
MODERNA | 22,685 | -1,90 % | Gescheiterte Impfstoffstudie belastet Moderna | ||
PAION | 0,017 | -24,11 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
VALNEVA | 4,114 | -0,53 % | Valneva-Aktie unter Druck - Anleger verlieren vorerst das Vertrauen in den Impfstoffhersteller! | ||
AMGEN | 253,30 | -0,71 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
EPIGENOMICS | 0,880 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
NOVAVAX | 7,113 | -2,36 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
STRYKER | 327,40 | -2,15 % | What You Need to Know Ahead of Stryker's Earnings Release | ||
BIOGEN | 127,00 | -0,24 % | Biogen Inc.: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 | Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality... ► Artikel lesen | |
BIOFRONTERA | 2,650 | +1,14 % | PTA-News: Biofrontera AG: Biofrontera AG schließt Verkauf der US-Vermögenswerte von Ameluz® und RhodoLED® an Biofrontera Inc. ab | DJ PTA-News: Biofrontera AG: Biofrontera AG schließt Verkauf der US-Vermögenswerte von Ameluz® und RhodoLED® an Biofrontera Inc. ab
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera... ► Artikel lesen |